+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06650501

Comparing Dabigatran and Oral Anti-Xa Inhibitors for Treatment of Staphylococcus aureus Bloodstream Infection

Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2026-09-24

300

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether switching to dabigatran improves outcomes for patients with Staphylococcus aureus bacteremia who are already taking oral anticoagulants called anti-Xa inhibitors apixaban, edoxaban, or rivaroxaban. Dabigatran is approved for similar uses and shows activity against S. aureus in laboratory and animal studies, as well as in a smaller trial. This trial is a sub-study within a larger Staphylococcus aureus Network Adaptive Platform SNAP trial. Participants are randomly assigned to continue their current anti-Xa inhibitor or switch to dabigatran at a dose approved for their condition, bleeding risk, and kidney function. The study compares these two approaches to see if dabigatran offers better results. The treatment period aligns with their clinical indication, and dosing is personalized based on individual factors. During the trial, participants will be monitored for clinical outcomes including safety events, treatment failure, and mortality, assessed 90 days after enrollment in the SNAP trial. Researchers will track serious adverse events, bleeding, blood clots, strokes, and heart-related events. Participants remain under medical supervision throughout, and study results will inform future research on anticoagulation in this infection setting.

CONDITIONS

Brief Title

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Research Team

F

Fatima Amari

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here